Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in ATTR-CM (Fx1B-303)
NCT00935012Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2009
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Pfizer. Started Sep 2009; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT00935012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00935012.